Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China

Fineline Cube Jan 20, 2026
Company Drug

D3 Bio’s KRAS Programs Advance: FDA Clears Phase I G12D Inhibitor D3S‑003 and Phase II G12C‑ERK Combo

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA

Fineline Cube Jun 5, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...

Company Deals

OBiO Technology Partners with Shenzhen Innovation Immunotechnology for TCR-T Cell Therapy Development

Fineline Cube Jun 5, 2024

OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading Contract Research Organization (CRO) specializing in...

Company Drug

Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia

Fineline Cube Jun 5, 2024

Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...

Company Drug

Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125

Fineline Cube Jun 5, 2024

Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received...

Company Deals Medical Device

BOE-Backed Genewise Bio Secures RMB 100 Million in Series A Financing for Molecular Diagnostics

Fineline Cube Jun 5, 2024

Genewise Bio, a molecular diagnostics company nurtured by BOE Technology Group, has reportedly secured RMB...

Company Drug

Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA

Fineline Cube Jun 5, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...

Hospital Policy / Regulatory

China’s NHC Mandates Urban Hospitals to Aid County-Level Medical Institutions

Fineline Cube Jun 5, 2024

The National Health Commission (NHC) has issued a notification aimed at further promoting the allocation...

Company Drug

Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial

Fineline Cube Jun 5, 2024

Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...

Company Drug

AstraZeneca’s Tagrisso Achieves Milestone Progression-Free Survival in Late-Stage Lung Cancer Study

Fineline Cube Jun 5, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from...

Company Drug

MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study

Fineline Cube Jun 5, 2024

MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...

Company Deals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Fineline Cube Jun 5, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...

Company Deals

Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases

Fineline Cube Jun 5, 2024

Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...

Company Drug

Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP

Fineline Cube Jun 4, 2024

Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...

Company Medical Device

Zylox-Tonbridge Medical Technology Earns NMPA Approval for First Vascular Stapler in China

Fineline Cube Jun 4, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices...

Company Deals Drug

Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody

Fineline Cube Jun 4, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...

Company Drug

Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs

Fineline Cube Jun 4, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...

Company

China Meheco Group Appoints Yang Guang as Chairman and Legal Representative

Fineline Cube Jun 4, 2024

China Meheco Group Co., Ltd (SHA: 600056) has announced the appointment of Yang Guang to...

Company Drug

Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China

Fineline Cube Jun 4, 2024

Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...

Company Drug

Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT

Fineline Cube Jun 4, 2024

Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...

Company Medical Device

Varian Medical Gets China Approval for Fourth-Generation Halcyon Radiotherapy System

Fineline Cube Jun 4, 2024

Varian Medical Systems (NYSE: VAR), a US-based leader in cancer treatment technology, has announced that...

Posts pagination

1 … 295 296 297 … 611

Recent updates

  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
  • D3 Bio’s KRAS Programs Advance: FDA Clears Phase I G12D Inhibitor D3S‑003 and Phase II G12C‑ERK Combo
  • Aidea’s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market
  • Blue Sail’s Lithonic IVL System Wins CE Mark for Coronary Calcified Lesions
  • Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China

Company Drug

D3 Bio’s KRAS Programs Advance: FDA Clears Phase I G12D Inhibitor D3S‑003 and Phase II G12C‑ERK Combo

Company Drug

Aidea’s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market

Company Medical Device

Blue Sail’s Lithonic IVL System Wins CE Mark for Coronary Calcified Lesions

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.